Loading...
Loading...
SNPX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 5.9M |
| Operating I/L | -5.9M |
| Other Income/Expense | 10.4M |
| Interest Income | 0.1M |
| Pretax | 4.5M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | 4.5M |
Synaptogenix, Inc. is a biopharmaceutical company focused on developing a product platform based on the drug candidate Bryostatin-1 for the treatment of Alzheimer's disease. The company also explores therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. generates revenue through its product candidates in pre-clinical and clinical development, as well as through licensing agreements with prominent institutions such as Stanford University and the Icahn School of Medicine at Mount Sinai.
